Nintedanib Esylate Patent Expiration

Nintedanib Esylate is Used for slowing the decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Ofev on Oct 15, 2014.


Nintedanib Esylate Patents

Given below is the list of patents protecting Nintedanib Esylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ofev US9907756

(Pediatric)

Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative Dec 07, 2029 Boehringer Ingelheim
Ofev US10105323

(Pediatric)

Pharmaceutical dosage form for immediate release of an indolinone derivative Dec 04, 2029 Boehringer Ingelheim
Ofev US9907756 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative Jun 07, 2029 Boehringer Ingelheim
Ofev US10105323 Pharmaceutical dosage form for immediate release of an indolinone derivative Jun 04, 2029 Boehringer Ingelheim
Ofev US10154990

(Pediatric)

Medicaments for the treatment or prevention of fibrotic diseases Jul 08, 2026 Boehringer Ingelheim
Ofev US6762180

(Pediatric)

Substituted indolines which inhibit receptor tyrosine kinases Apr 01, 2026 Boehringer Ingelheim
Ofev US10154990 Medicaments for the treatment or prevention of fibrotic diseases Jan 08, 2026 Boehringer Ingelheim
Ofev US6762180 Substituted indolines which inhibit receptor tyrosine kinases Oct 01, 2025 Boehringer Ingelheim
Ofev US7989474 Use of Lck inhibitors for treatment of immunologic diseases Apr 06, 2024

(Expired)

Boehringer Ingelheim
Ofev US7119093 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition Feb 21, 2024

(Expired)

Boehringer Ingelheim



Nintedanib Esylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List